newsfilter
← Latest News
Business Wire·

Appili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis Pharmaceuticals

Agreement expanded to add European and Latin American markets NDA filing with US FDA for Appili's ATI-1501 expected later this year Appili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused o